The in vivo regional distribution of ['*F]GBR 13119 (l-[(4-['8F]fluorophenyl(phenyl)methoxy)ethyl]-4-(3-phenylpropyl)piperazine), a specific dopamine reuptake inhibitor, was examined in brains of C57BL/6 mice after MPTP treatment. At 2 weeks post MPTP the in vivo specific binding of ['*F]GBR 13119 in striatum was decreased 63% relative to age and sex-matched controls. Animals studied at 6 and 8 weeks after MPTP treatment showed a eradual recoverv of soecific I'sFIGBR 13119 bindine in the striatum. No significant changes were observed-in binding of radiotracer to'cerebellum or cortex after MPTP treatment, nor were age-related changes observed in control mice. In vivo radiotracer studies thus appear useful for following gradual changes in the dopamine uptake system of mouse brain after neurotoxin treatment.
Introduction
Although the MPTP (I-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-treated mouse has seen extensive use as a model of Parkinson's disease (review: Kopin and Markey, 1988) , it differs from idiopathic parkinsonism in that the onset of neuronal degeneration is very rapid and is followed by slow recovery of the dopaminergic system. The return of endogenous dopamine levels to higher levels is now well documented (Kopin and Markey, 1988; Ricuarte er af., 1987) . Similar changes in the neuronal dopamine reuptake system, which is responsible for termination of neurotransmission by removal of dopamine from the synapse, have been reported using in vitro methods. After MPTP treatment there is a rapid decline in DA uptake (V,,,, using [3H] dopamine: Jossan et al., 1989; Ricuarte et al., 1987) , and decreased binding of ['Hlmazindol to the DA transporter site in striatal synaptosomal preparations (Ricuarte er af., 1987; Sershen et al., 1985; Sundstrum et al., 1988) or striatal tissue by in vitro autoradiography (Donnan et al., 1987) . The dopamine reuptake system also appears to recover with time, and the number of DA uptake sites as determined by in *All correspondence should be addressed to: Dr Michael R. Kilboum Haka, 1988; Haka et al., 1989) for the in vivo study of the DA uptake system, and have recently reported the regional in uivo binding and pharmacological specificity of these radioligands in mouse, rat, monkey and human brain (Kilbourn, 1988; Kilbourn et al., 1989a, b; Ciliax er al., 1990; Koeppe et al., 1990) . Although the MPTP rodent has been extensively studied using in vitro techniques, very few in vivo experiments have been reported, mostly due to the lack of suitable radioligands. A thorough understanding of the extent and time course of recovery of the dopaminergic system in MPTP-treated rodents will be important in the interpretation of results of studies into new preventative or therapeutic strategies for neurodegenerative diseases such as Parkinson's disease. The availability of new radioligands such as ['"FIGBR 13119 and [18F] GBR 12909, which can be synthesized in high specific activity (>2000 Ci/mmol), makes possible in uivo studies of the DA reuptake system in the MPTP mouse model. We report here that [18F]GBR 13119 can be used to demonstrate in viuo loss of DA reuptake sites after MPTP treatment, and furthermore that this in uivo radiotracer technique has the sensitivity to show the gradual recovery of this nemotransmitter reuptake system.
Discussion

Materials and Methods
["F]GBR 13119 (specific activity > 2000 Ci/mmol) was prepared according to literature methods (Kilbourn and Haka, 1988; Haka et al., 1989) . MPTP was prepared by the methylation of 4-hydroxy-4-phenylpiperidine (Aldrich Chem. Co.) followed by acid-catalyzed dehydration. Mice (C57BL/6, male, 25-30 g, 13-l 5 weeks: Charles River) were injected four times with 10 mg/kg i.p. MPTP at 1 h intervals (Ricuarte et al., 1987) . Animals were then used for brain biodistribution studies at 2, 6 and 8 weeks following MPTP treatment; at each time point an equal number of control animals, age-and sexmatched, were also studied. Mice (controls or MPTPlesioned) were injected via the tail vein with 3-10 PCi of ['*F]GBR 13119 (< 1 ng/kg, in isotonic saline). At 60 min the animals were killed by decapitation, and the brain rapidly removed and dissected into regions of interest (striatum, cortex, cerebellum, rest of brain) and a blood sample obtained. The tissue samples were then weighed and counted for fluorine-18. Data were calculated as % injected dose/g (% I.D./g) for all tissues, and analyzed for significance using an unpaired Student's t-test.
['*F]GBR 13119 is a high affinity radioligand for the dopamine uptake site which shows good pharmacological selectivity in viuo (Kilbourn, 1988; Kilbourn ef al., 1989a, b; Ciliax et al., 1990) . The specific binding of this radioligand to sites in the striatum of mice is significantly decreased (63%) at 2 weeks after systemic MPTP treatment (Table 1) . This is similar to in vitro decreases of 40-80% in [3H]mazindol binding to striatal tissue (Ricuarte et al., 1986; Sershen et al., 1985; Sundstrom et al., 1988) and losses of dopamine of as much as 80% (Nishi et al., 1989; Ricuarte et al., 1987; Sundstrom et al., 1988) . No significant changes were observed in ['*F]GBR 13 119 binding in cortex or cerebellum. Cerebellar radioactivity levels should represent mostly non-specific binding, as no dopamine uptake sites have been observed in the cerebellum using in vitro autoradiography (['Hlmazindol: Donnan et al., 1989) or photoaffinity labeling experiments (Grigoriadis et al., 1989) . We have consistently observed slightly higher cortical ['*F]GBR 13119 levels (cortex/cerebellum values of 1.1-I .3), but this binding (if to DA uptake sites) may not be affected by MPTP treatment.
Results
The time course study of ['*F]GBR 13119 binding (Table 1) shows a gradual recovery of the striatal DA uptake system over the 8 week period: full recovery has not been achieved, as STR/CER ratios remain depressed at the end of the study. This is consistent with the demonstration of recovery of dopamine uptake sites in vitro using [jH]mazindol binding to mouse brain striatal membranes (Donnan et al., 1987) , where control values were reached after 1 year. At 2 weeks after MPTP treatment there is a ['*F]GBR 13119 would thus appear a suitable significant loss of in vivo ['*F]GBR 13119 binding to marker for dopaminergic terminals in the striatum of mouse striatum (Table 1) . The data are presented mice, and the loss and subsequent recovery of DA both as regional brain distributions (% I.D./g) and uptake sites after MPTP treatment have for the first target to non-target ratios (% I.D. striatum/% I.D.
time been demonstrated using in uivo radiotracer cerebellum; STR/CER). The STR/CER ratios were techniques. The recovery of DA reuptake sites with statistically identical between all control groups time is consistent with the proposals of regrowth of demonstrating no age-related dependence of the dopaminergic terminals from areas which are less dopamine uptake system during the time period sensitive to the toxin (ventral tegmental area, sub-(13-24 weeks) studied here; this is consistent with the stantia nigra) (Donnan et al., 1987; Kopin and literature (Jonec and Finch, 1975; Strong et al., 1984 ) Markey, 1988 . The availability of such high specific and therefore all control animals were combined into activity, specific radioligands for in viuo studies elima single group. The loss of specific ['*F]GBR 13 119 inates possible problems with using less specific radiobinding in the striatum [defined here as % I.D. STR ligands such as [3H]mazindol or [3H]nomifensine, minus % I.D. CER, where cerebellum is assumed to be which bind to both dopamine and norepinephrine completely void of dopaminergic terminals (Grigorireuptake sites. The use of ["F]GBR 13119 may also adis et al., 198911 at 2 weeks is approx. 63% (controls, avoid difficulties with the use of [3H]GBR 12935 and 1.02 + 0.12; MPTP-treated, 0.382 + 0.22, P < 0.006).
in vitro analysis methods, in which a second binding Table I (Andersen, 1987 (Andersen, , 1989 Andersen et al., 1987) representing changes in the number of dopaminergic terminals. In this study, specific binding was estimated using simple target to non-target ratios: application to human studies using PET may require more complex pharmacokinetic modeling approaches (Koeppe et al.. 1990). Such studies may be of considerable value in the study of new pharmacological approaches to prevent or treat degeneration of this
